RxDoctor Payments Data

Lianter Albert, MD

Internal Medicine · Morgan City, LANPI 1407848591

Payments from drug & device makers

$860in general payments, 2019–2025

Across 34 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$404
  • Novo Nordisk$291
  • Bayer$111
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25
  • Idorsia Pharmaceuticals US Inc$15
  • Boehringer Ingelheim$15

What the payments were for

  • Food & beverage$84598%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$860 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,644
Medicare patients
79
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$41,774
JanuviaSitagliptin Phosphate37$35,377
TrulicityDulaglutide26$25,499
MounjaroTirzepatide20$25,049
EliquisApixaban28$24,520
JardianceEmpagliflozin12$20,333
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen718$16,173
Tresiba Flextouch U-200Insulin Degludec26$13,403
FarxigaDapagliflozin Propanediol12$12,714
LinzessLinaclotide13$12,382
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,632
Semglee (Yfgn) PenInsulin Glargine-Yfgn12$4,661
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$4,396
Gabapentin364$3,346
Sucralfate27$2,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$291$41,77437 claims
Boehringer IngelheimJardiance$15$20,33312 claims
AbbVieLinzess, Synthroid$404$13,61736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Morgan City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →